Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Discovery of Vilaprisan (BAY 1002670): A Highly Potent and Selective Progesterone Receptor Modulator Optimized for Gynecologic Therapies.

Möller C, Bone W, Cleve A, Klar U, Rotgeri A, Rottmann A, Schultze-Mosgau MH, Wagenfeld A, Schwede W.

ChemMedChem. 2018 Nov 6;13(21):2271-2280. doi: 10.1002/cmdc.201800487.

PMID:
30407750
2.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A.

Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16.

PMID:
30115664
3.

BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies.

Wagenfeld A, Bone W, Schwede W, Fritsch M, Fischer OM, Moeller C.

Hum Reprod. 2013 Aug;28(8):2253-64. doi: 10.1093/humrep/det247. Epub 2013 Jun 5.

PMID:
23739217
4.

Pharmacology and clinical use of sex steroid hormone receptor modulators.

Cleve A, Fritzemeier KH, Haendler B, Heinrich N, Möller C, Schwede W, Wintermantel T.

Handb Exp Pharmacol. 2012;(214):543-87. doi: 10.1007/978-3-642-30726-3_24. Review.

PMID:
23027466
5.

Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system.

Afhüppe W, Sommer A, Müller J, Schwede W, Fuhrmann U, Möller C.

J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):105-15. doi: 10.1016/j.jsbmb.2008.11.015. Epub 2008 Dec 14.

PMID:
19130882
6.

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone.

Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, Panaretakis T, Siemeister G, Lage H, Nanty L, Hammer S, Mittelstaedt K, Winsel S, Eschenbrenner J, Castedo M, Demarche C, Klar U, Kroemer G.

Cancer Res. 2008 Jul 1;68(13):5301-8. doi: 10.1158/0008-5472.CAN-08-0237.

7.

Investigational developments for the treatment of progesterone-dependent diseases.

Möller C, Hoffmann J, Kirkland TA, Schwede W.

Expert Opin Investig Drugs. 2008 Apr;17(4):469-79. doi: 10.1517/13543784.17.4.469 . Review.

PMID:
18363513
8.

Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development.

Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB.

Angew Chem Int Ed Engl. 2006 Dec 4;45(47):7942-8. No abstract available.

PMID:
17006870
9.

Subcellular distribution of epothilones in human tumor cells.

Lichtner RB, Rotgeri A, Bunte T, Buchmann B, Hoffmann J, Schwede W, Skuballa W, Klar U.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11743-8. Epub 2001 Sep 18.

10.

Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.

Fuhrmann U, Hess-Stumpp H, Cleve A, Neef G, Schwede W, Hoffmann J, Fritzemeier KH, Chwalisz K.

J Med Chem. 2000 Dec 28;43(26):5010-6.

PMID:
11150172
11.

Synthesis and biological activity of 11,19-bridged progestins.

Schwede W, Fritzemeier KH, Halfbrodt W, Krattenmacher R, Muhn P, Neef G, Ottow E, Schöllkopf K.

Steroids. 1998 Mar;63(3):166-77.

PMID:
9558718
12.

Synthesis and biological activity of 17-chloro-16(17) unsaturated D-homo antiprogestins.

Schwede W, Cleve A, Neef G, Ottow E, Stöckemann K, Wiechert R.

Steroids. 1994 Mar;59(3):176-80.

PMID:
8048148

Supplemental Content

Loading ...
Support Center